← back to search

Debu Tripathy

The University of Texas MD Anderson Cancer Center · US
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, and Cancer Treatment and Pharmacology.
h-index
69
citations
25,833
works
1,163
NIH funding
primary concept
Medicine
email

Recent publications

AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization
Breast Cancer Research 2025cited by 7position: middledoi
Abstract LB480: Cryogenic volume electron microscopy reveals restoration of organelle integrity by abemaciclib in hormone receptor-positive, HER2-negative metastatic breast cancer organoids
Cancer Research 2025cited by 0position: middledoi
Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update
Journal of Clinical Oncology 2024cited by 187position: middledoi
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer: final results from the POLARIS trial
The Oncologist 2024cited by 10position: firstdoi
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
Cancer Cell 2023cited by 162position: middledoi
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
Annals of Oncology 2023cited by 86position: middledoi
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Clinical Cancer Research 2023cited by 18position: middledoi
Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
Biomedicines 2023cited by 9position: middledoi
Challenges in Implementing Guideline on Integrative Oncology and Pain: The Israeli Perspective
Journal of Pain and Symptom Management 2023cited by 4position: middledoi
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer
Clinical Cancer Research 2022cited by 40position: middledoi
Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study
Cancer Research 2022cited by 27position: middledoi
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases
JAMA Oncology 2022cited by 23position: firstdoi
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)
Cancer Research 2021cited by 88position: middledoi
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
Nature Communications 2021cited by 72position: middledoi
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
npj Breast Cancer 2021cited by 52position: middledoi
NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis
JNCI Journal of the National Cancer Institute 2021cited by 50position: middledoi
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
Annals of Oncology 2021cited by 45position: middledoi
Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.
Journal of Clinical Oncology 2021cited by 30position: middledoi
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
npj Breast Cancer 2021cited by 29position: middledoi
Aerobic and resistance exercise improve patient-reported sleep quality and is associated with cardiometabolic biomarkers in Hispanic and non-Hispanic breast cancer survivors who are overweight or obese: results from a secondary analysis
SLEEP 2021cited by 27position: lastdoi
Stereotactic radiosurgery (SRS) for brain metastasis (BM) in hormone receptor positive (HR+) HER2 negative breast cancer (BC).
Journal of Clinical Oncology 2021cited by 0position: middledoi
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
Annals of Oncology 2020cited by 433position: middledoi
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
Annals of Oncology 2020cited by 105position: middledoi
Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.
Journal of Clinical Oncology 2020cited by 66position: middledoi
Hispanic ethnicity as a moderator of the effects of aerobic and resistance exercise on physical fitness and quality-of-life in breast cancer survivors
Journal of Cancer Survivorship 2020cited by 23position: middledoi
Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: <scp>MD</scp> Anderson Cancer Center experience
International Journal of Cancer 2020cited by 21position: middledoi
Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype
British Journal of Cancer 2020cited by 7position: middledoi
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
New England Journal of Medicine 2019cited by 1,016position: lastdoi
Effect of Aerobic and Resistance Exercise Intervention on Cardiovascular Disease Risk in Women With Early-Stage Breast Cancer
JAMA Oncology 2019cited by 78position: middledoi
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea
Breast Cancer Research and Treatment 2019cited by 72position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Hope S. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center10 papers (2012–2019)Peter A. Kaufman · University of Vermont8 papers (2012–2019)Denise A. Yardley · Lublin Oncology Center8 papers (2012–2019)Wendy Demark‐Wahnefried · University of Alabama at Birmingham7 papers (2014–2021)Christina M. Dieli‐Conwright · Boston University7 papers (2014–2021)Adam Brufsky · UPMC Hillman Cancer Center7 papers (2012–2019)Leslie Bernstein · Beckman Research Institute7 papers (2014–2021)Kerry S. Courneya · Royal Alexandra Hospital7 papers (2014–2021)Thomas A. Buchanan · Keck Hospital of USC7 papers (2014–2021)Darcy Spicer · University of Southern California6 papers (2018–2021)Joanne Mortimer · University of Alabama at Birmingham6 papers (2014–2020)Akshara Singareeka Raghavendra · Cambridge University Hospitals NHS Foundation Trust6 papers (2017–2021)Nathalie Sami · University of Southern California6 papers (2018–2021)Sara A. Hurvitz · University of Washington Applied Physics Laboratory5 papers (2014–2019)Marianne Ulcickas Yood · Nutrasource5 papers (2012–2014)Musa Mayer · UPMC Hillman Cancer Center5 papers (2012–2014)Kyuwan Lee · Ewha Womans University5 papers (2018–2020)Cheng S. Quah · Principia Biopharma (United States)4 papers (2012–2014)Aditya Bardia · Comprehensive Blood & Cancer Center4 papers (2019–2023) · 4 papers (2013–2014)